At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,216 enrolled
Drug / intervention
Indacaterol acetate/Mometasone furoate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma
In Brief
A Phase 3 clinical trial evaluating Indacaterol acetate/Mometasone furoate, Mometasone furoate, and 1 other intervention for Asthma. Completed, enrolled 2,216 participants across 388 sites in 24 countries.
Detailed Summary
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBulgaria, China, Croatia, Czechia, Egypt, Estonia, Germany, Guatemala, Hungary, India, Ireland, Japan, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartDec 2015
Primary CompletionNov 2018
Study CompletionJun 2019
TodayJul 2026
First PostedSep 18, 2015
Enrollment StartDec 29, 2015
Primary CompletionNov 21, 2018
Study CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.8 years ago
Interventions
Indacaterol acetate/Mometasone furoatedrug
Mometasone furoatedrug
Salmeterol xinafoate/fluticasone propionatedrug